English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Somatic amplifications of the  LYL1  gene are relatively common occurrences in patients who develop uterine corpus endometrial carcinoma (UCEC) as opposed to other cancers. This study was undertaken to determine whether such genetic alterations affect survival outcomes of UCEC.    Methods  In 370 patients with UCEC, we analysed clinicopathologic characteristics and corresponding genomic data from The Cancer Genome Atlas database. Patients were stratified according to  LYL1  gene status, grouped as amplification or non-amplification. Heightened levels of cancer-related genes expressed in concert with  LYL1  amplification were similarly investigated through differentially expressed gene and gene set enrichment analyses. Factors associated with survival outcomes were also identified.    Results  Somatic  LYL1  gene amplification was observed in 22 patients (5.9%) with UCEC. Patients displaying amplification (vs. non-amplification) were significantly older at the time of diagnosis and more often were marked by non-endometrioid, high-grade, or advanced disease. In survival analysis, the amplification subset showed poorer progression-free survival (PFS) and overall survival (OS) rates (3-year PFS: 34.4% vs. 79.9%,  P  = 0.031; 5-year OS: 25.1% vs. 84.9%,  P  = 0.014). However, multivariate analyses adjusted for tumor histologic type, grade, and stage did not confirm  LYL1  gene amplification as an independent prognostic factor for either PFS or OS. Nevertheless, MAPK, WNT, and cell cycle pathways were significantly enriched by  LYL1  gene amplification ( P  < 0.001,  P  = 0.002, and  P  = 0.004, respectively).    Conclusions  Despite not being identified as an independent prognostic factor in UCEC,  LYL1  gene amplification is associated with other poor prognostic factors and correlated with upregulation of cancer-related pathways.    Electronic supplementary material  The online version of this article (10.1186/s12885-018-4429-z) contains supplementary material, which is available to authorized users.

LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data